Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

Journal of Virology

Volumn 76, Issue 15, 2002, Pages 7760-7776

  Schülke, Norbert ^a   Vesanen, Mika S ^a   Sanders, Rogier W ^a   Zhu, Ping ^a   Lu, Min ^a   Anselma, Deborah J ^a   Villa, Anthony R ^a   Parren, Paul W H I ^a   Binley, James M ^a   Roux, Kenneth H ^a   Maddon, Paul J ^a   Moore, John P ^a   Olson, William C ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CONFORMATIONAL TRANSITION; COVALENT BOND; DISULFIDE BOND; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN STABILITY; SURFACE PLASMON RESONANCE; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; DIMERIZATION; DISULFIDES; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HUMANS; MICROSCOPY, IMMUNOELECTRON; MODELS, MOLECULAR; PROTEIN CONFORMATION; RADIOIMMUNOPRECIPITATION ASSAY; SURFACE PLASMON RESONANCE; TRANSFECTION;

EID: 0036315133     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.15.7760-7776.2002     Document Type: Article

References (93)

1. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates
2. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
3. Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines
4. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
5. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
6. The antibody response in HIV-1 infection
7. Efficient neutralization of primary, isolates of HIV-1 by a recombinant human monoclonal antibody
8. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41
9. Monomer-trimer equilibrium of the ectodomain of SIV gp41: Insight into the mechanism of peptide inhibition of HIV infection
10. Core structure of gp41 from the HIV envelope glycoprotein
11. Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160
12. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation
13. + T-cell-depleted rhesus macaques
14. HIV-1 membrane fusion: Targets of opportunity
15. Paramyxovirus fusion (F) protein: A conformational change on cleavage activation
16. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein
17. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
18. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
19. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
20. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein
21. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain
22. The first step: Activation of the Semliki Forest virus spike protein precursor causes a localized conformational change in the trimeric spike
23. SPIDER and WEB: Processing and visualization of images in 3D electron microscopy and related fields
24. Self-assembly of apoferritin from horse spleen after reversible chemical modification with 2,3-dimethylmaleic anhydride
25. SWISS-MODEL and the Swiss-Pdb-Viewer: An environment for comparative protein modeling
26. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis
27. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein
28. A biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies and HIV-1 Env to chemokine receptors
29. Analysis of data from the analytical ultracentrifuge by nonlinear least squares techniques
30. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies
31. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors
32. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(→Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site
33. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
34. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
35. High molecular-weight polymers in human albumin solutions. Quantitative determination by polyacrylamide gradient electrophoresis
36. Computer-aided interpretation of analytical sedimentation data for proteins
37. Identification of viral mutants by mass spectrometry
38. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
39. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion
40. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
41. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
42. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
43. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1
44. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
45. Energetics of the HIV gp120-CD4 binding reaction
46. The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing
47. Structural localization of the E3 glycoprotein in attenuated Sindbis virus mutants
48. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing antibody, 2F5
49. The antiviral activity of antibodies in vitro and in vivo
50. In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope
51. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
52. gp120: Biologic aspects of structural features
53. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene
54. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
55. Immunoelectron microscopy of idiotype-anti-idiotype complexes
56. Negative-stain immunoelectron-microscopic analysis of small macromolecules of immunologic significance
57. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
58. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
59. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
60. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
61. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development
62. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis
63. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form
64. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions
65. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin
66. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates
67. Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate
68. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
69. Atomic structure of a thermostable subdomain of HIV-1 gp41
70. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
71. Yeast KEX2 endopeptidase correctly cleaves a neuroendocrine prohormone in mammalian cells
72. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
73. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
74. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2
75. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
76. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
77. A comparative review of the structure and biosynthesis of thyroglobulin
78. Atomic structure of the ectodomain from HIV-1 gp41
79. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope
80. The extracellular domain of immunodeficiency virus gp41 protein: Expression in Escherichia coli, purification, and crystallization
81. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
82. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein
83. The antigenic structure of the HIV gp120 envelope glycoprotein
84. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
85. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
86. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
87. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
88. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1
89. Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies
90. Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer
91. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic
92. Structural flexibility and functional valency of CD4-IgG2 (PRO 542): Potential for crosslinking HIV-1 envelope spikes
93. Broadly neutralizing antibodies targeted to the membrane proximal external region of human immunodeficiency virus type 1 glycoprotein gp41